Can at-home tDCS really help with depression?

A 2024 Nature Medicine trial tested tDCS — a gentle electrical current delivered through a headset at home — against a convincing fake. Here's what the results actually say.

What they did. 174 adults with moderate-to-severe depression were randomly assigned to either real tDCS or a convincing sham device, used at home for 10 weeks. Researchers supervised remotely by video. Neither patients nor raters knew which device was which — the gold-standard setup for a fair test.

What tDCS is. Electrodes on the forehead deliver a low, steady current (2 mA) to a mood-regulating region of the prefrontal cortex. Sessions last 30 minutes. No medication, no surgery, no sedation.

What happened. Both groups improved in the first week. After that, the real-tDCS group kept improving while the sham group leveled off. By week 10, depression scores (MADRS) had dropped an average of 11.3 points on real tDCS versus 7.7 on sham. More importantly, roughly 2 out of 3 people on real tDCS responded to treatment, and more than half reached remission — about twice the rates seen in the sham group.

What it didn't study. The trial ran 10 weeks of blinded treatment plus a 10-week open-label phase where everyone got real tDCS. It did not track relapse after treatment ended — an open question for anyone weighing tDCS long-term.

Safety. No serious device-related adverse events. The most common side effect was mild skin redness under the electrodes. No cases of mania or serious psychiatric events were linked to the device.

Woodham et al., Nature Medicine (2025, published online Oct 2024). NCT05202119.

Depression scores over 10 weeks

Lower MADRS score = less severe depression · n = 173

Active tDCS (real)

Sham tDCS (placebo)

How to read it: Vertical bars show statistical uncertainty (±1 standard error). ✱✱ marks weeks where the gap between groups was very unlikely to be chance (p < 0.01).

Response & remission

The clinical outcomes that matter most — rates were roughly 2× higher with real tDCS.

Treatment response

64% vs. 32% on sham

Share of participants whose depression score fell by half or more by week 10 (MADRS). p < 0.001

Clinical remission

58% vs. 29% on sham

Share of participants whose scores dropped to the "well" range (MADRS ≤ 10) by week 10. p = 0.002

Serious device events

0 across 173 participants

The most common side effect was mild skin redness. No mania, no serious psychiatric events linked to the device.

The honest bottom line

This is one of the strongest positive trials of tDCS for depression to date: fully at-home, well-blinded, and with response and remission rates about twice those of placebo. It adds meaningful weight to the case for tDCS as a real option — particularly for people who want a drug-free, non-invasive path or who haven't responded well to medication alone.

These are group averages — individual results vary. Talk with a clinician before starting any treatment.

Source: Woodham RD, et al. Home-based transcranial direct current stimulation treatment for major depressive disorder: a fully remote phase 2 randomized sham-controlled trial. Nature Medicine, 2025. · Educational content — not medical advice.